Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study
Objectives: Tenofovir alafenamide (TAF) is a preferred nucleotide reverse transcriptase inhibitor used in the treatment of HIV. Co-administration of TAF with rifabutin (RFB) is not recommended due to concerns that RFB decreases TAF gastrointestinal absorption. The objective of this study was to dete...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-11-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971220321391 |
| _version_ | 1811333300273283072 |
|---|---|
| author | Thomas C.S. Martin Lucas A. Hill Michael E. Tang Shannon M. Balcombe |
| author_facet | Thomas C.S. Martin Lucas A. Hill Michael E. Tang Shannon M. Balcombe |
| author_sort | Thomas C.S. Martin |
| collection | DOAJ |
| description | Objectives: Tenofovir alafenamide (TAF) is a preferred nucleotide reverse transcriptase inhibitor used in the treatment of HIV. Co-administration of TAF with rifabutin (RFB) is not recommended due to concerns that RFB decreases TAF gastrointestinal absorption. The objective of this study was to determine the efficacy of antiretroviral therapy regimens that include the co-administration of TAF and RFB. Methods: Persons with HIV (PWH) who received TAF–RFB co-administration for ≥1 month were identified retrospectively. The primary outcome was the maintenance of HIV viral load <200 copies/mL (cpm) for those already on HIV therapy at RFB initiation, or suppression of viral load to <200 cpm for those with unsuppressed HIV viral load prior to TAF–RFB co-administration. Results: Twenty-two PWH met the inclusion criteria. Four out of five patients (80%) maintained a viral load <200 cpm and 15/17 (88%) achieved a viral load <200 cpm during TAF–RFB co-administration. After the exclusion of patients who self-discontinued therapy or were lost to follow-up, 19/19 (100%) met the combined primary endpoint of HIV viral load <200 cpm. Conclusions: This study suggests that TAF–RFB co-administration may be effective despite concerns that RFB could reduce TAF absorption. |
| first_indexed | 2024-04-13T16:50:37Z |
| format | Article |
| id | doaj.art-e37b8aa1d4a44851b5e35e7bf079bda9 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-04-13T16:50:37Z |
| publishDate | 2020-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-e37b8aa1d4a44851b5e35e7bf079bda92022-12-22T02:38:57ZengElsevierInternational Journal of Infectious Diseases1201-97122020-11-01100470472Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational studyThomas C.S. Martin0Lucas A. Hill1Michael E. Tang2Shannon M. Balcombe3Corresponding author.; Division of Infectious Diseases and Global Public Health, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USADivision of Infectious Diseases and Global Public Health, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USADivision of Infectious Diseases and Global Public Health, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USADivision of Infectious Diseases and Global Public Health, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USAObjectives: Tenofovir alafenamide (TAF) is a preferred nucleotide reverse transcriptase inhibitor used in the treatment of HIV. Co-administration of TAF with rifabutin (RFB) is not recommended due to concerns that RFB decreases TAF gastrointestinal absorption. The objective of this study was to determine the efficacy of antiretroviral therapy regimens that include the co-administration of TAF and RFB. Methods: Persons with HIV (PWH) who received TAF–RFB co-administration for ≥1 month were identified retrospectively. The primary outcome was the maintenance of HIV viral load <200 copies/mL (cpm) for those already on HIV therapy at RFB initiation, or suppression of viral load to <200 cpm for those with unsuppressed HIV viral load prior to TAF–RFB co-administration. Results: Twenty-two PWH met the inclusion criteria. Four out of five patients (80%) maintained a viral load <200 cpm and 15/17 (88%) achieved a viral load <200 cpm during TAF–RFB co-administration. After the exclusion of patients who self-discontinued therapy or were lost to follow-up, 19/19 (100%) met the combined primary endpoint of HIV viral load <200 cpm. Conclusions: This study suggests that TAF–RFB co-administration may be effective despite concerns that RFB could reduce TAF absorption.http://www.sciencedirect.com/science/article/pii/S1201971220321391Tenofovir alafenamideHIVRifabutinCo-administration |
| spellingShingle | Thomas C.S. Martin Lucas A. Hill Michael E. Tang Shannon M. Balcombe Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study International Journal of Infectious Diseases Tenofovir alafenamide HIV Rifabutin Co-administration |
| title | Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study |
| title_full | Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study |
| title_fullStr | Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study |
| title_full_unstemmed | Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study |
| title_short | Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study |
| title_sort | tenofovir alafenamide and rifabutin co administration does not lead to loss of hiv 1 suppression a retrospective observational study |
| topic | Tenofovir alafenamide HIV Rifabutin Co-administration |
| url | http://www.sciencedirect.com/science/article/pii/S1201971220321391 |
| work_keys_str_mv | AT thomascsmartin tenofoviralafenamideandrifabutincoadministrationdoesnotleadtolossofhiv1suppressionaretrospectiveobservationalstudy AT lucasahill tenofoviralafenamideandrifabutincoadministrationdoesnotleadtolossofhiv1suppressionaretrospectiveobservationalstudy AT michaeletang tenofoviralafenamideandrifabutincoadministrationdoesnotleadtolossofhiv1suppressionaretrospectiveobservationalstudy AT shannonmbalcombe tenofoviralafenamideandrifabutincoadministrationdoesnotleadtolossofhiv1suppressionaretrospectiveobservationalstudy |